Phase 3Active, not recruiting
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy (MARITIME-OSA-1)
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living With Overweight or Obesity
- Sponsor
- Amgen (Industry)
- Enrolment
- 250 planned
- Conditions
- Obesity; Obstructive Sleep Apnea
- Interventions
- Maridebart cafraglutide; Placebo
- Ages
- adults, older adults
- Registry
- NCT07225686
From the registry
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.
Primary outcomes
- Change in Apnea-Hypopnea Index (AHI) from baseline at week 52